59
Participants
Start Date
November 1, 2012
Primary Completion Date
August 8, 2017
Study Completion Date
August 8, 2017
Anti-Endoglin Chimeric Monoclonal Antibody TRC105
Given IV
Bevacizumab
Given IV
Laboratory Biomarker Analysis
Correlative studies
Pharmacological Study
Correlative studies
National Taiwan University Hospital, Taipei
Royal Prince Alfred Hospital, Camperdown
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
University of Maryland/Greenebaum Cancer Center, Baltimore
Virginia Commonwealth University/Massey Cancer Center, Richmond
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
Moffitt Cancer Center, Tampa
Vanderbilt University/Ingram Cancer Center, Nashville
Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard, Fort Wayne
Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne
University of Michigan Comprehensive Cancer Center, Ann Arbor
Wayne State University/Karmanos Cancer Institute, Detroit
University of Iowa/Holden Comprehensive Cancer Center, Iowa City
Metro Minnesota Community Oncology Research Consortium, Saint Louis Park
Mayo Clinic, Rochester
NorthShore University HealthSystem-Glenbrook Hospital, Glenview
NorthShore University HealthSystem-Evanston Hospital, Evanston
Ingalls Memorial Hospital, Harvey
University of Chicago Comprehensive Cancer Center, Chicago
Decatur Memorial Hospital, Decatur
Washington University School of Medicine, St Louis
M D Anderson Cancer Center, Houston
University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora
USC / Norris Comprehensive Cancer Center, Los Angeles
City of Hope Comprehensive Cancer Center, Duarte
City of Hope South Pasadena, South Pasadena
University of California Davis Comprehensive Cancer Center, Sacramento
University of Colorado, Denver
Rutgers Cancer Institute of New Jersey, New Brunswick
Penn State Milton S Hershey Medical Center, Hershey
National Cancer Institute (NCI)
NIH